BNTX

BNTX

USD

BioNTech SE American Depositary Share

$104.780+0.460 (0.441%)

リアルタイム価格

Healthcare
バイオテクノロジー
ドイツ

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$104.320

高値

$107.000

安値

$104.215

出来高

0.13M

企業ファンダメンタルズ

時価総額

25.2B

業種

バイオテクノロジー

Germany

取引統計

平均出来高

0.85M

取引所

NMS

通貨

USD

52週レンジ

安値 $81.2現在値 $104.780高値 $129.27

関連ニュース

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on BioNTech, Raises Price Target to $140

HC Wainwright & Co. analyst Robert Burns maintains BioNTech with a Buy and raises the price target from $136 to $140.

もっと見る
HC Wainwright & Co. Maintains Buy on BioNTech, Raises Price Target to $140
GlobeNewswire

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemonstrated encouraging

もっと見る
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
GlobeNewswire

BioNTech to Host Innovation Series R&D Day on November 11, 2025

MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3:00

もっと見る
BioNTech to Host Innovation Series R&D Day on November 11, 2025
GlobeNewswire

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

MAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the third quarter 2025 on Monday, November 3, 2025. Additionally, the

もっと見る
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
Analyst Upgrades

JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $120

JP Morgan analyst Jessica Fye maintains BioNTech with a Neutral and lowers the price target from $121 to $120.

もっと見る
JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $120
GlobeNewswire

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next milestone in the execution of its oncology

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。